Bausch Health Companies (TSE:BHC) Shares Down 7.9%

Bausch Health Companies Inc. (TSE:BHC)’s stock price fell 7.9% during trading on Thursday . The stock traded as low as C$11.05 and last traded at C$11.08. 151,303 shares were traded during trading, a decline of 57% from the average session volume of 350,637 shares. The stock had previously closed at C$12.03.

Analyst Ratings Changes

Separately, Royal Bank of Canada boosted their target price on shares of Bausch Health Companies from C$8.00 to C$9.00 and gave the stock a “sector perform” rating in a research report on Friday, February 23rd.

Bausch Health Companies Trading Down 3.3 %

The firm has a market capitalization of C$3.90 billion, a PE ratio of -4.85, a PEG ratio of 0.21 and a beta of 0.83. The firm’s fifty day moving average is C$12.60 and its two-hundred day moving average is C$11.13. The company has a debt-to-equity ratio of 7,583.76, a current ratio of 1.30 and a quick ratio of 0.58.

Bausch Health Companies (TSE:BHC) last released its quarterly earnings results on Thursday, February 22nd. The company reported C$1.55 earnings per share for the quarter, topping the consensus estimate of C$1.36 by C$0.19. Bausch Health Companies had a negative net margin of 6.76% and a negative return on equity of 686.52%. The business had revenue of C$3.28 billion for the quarter, compared to analysts’ expectations of C$3.05 billion. On average, equities analysts predict that Bausch Health Companies Inc. will post 4.9511278 EPS for the current fiscal year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.